# Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

> **NCT04064905** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Zika Virus

## Interventions

- **BIOLOGICAL:** mRNA-1893
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04064905
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2021-03-22
- **Final completion:** 2021-03-22
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064905, "Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04064905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*